The Journal of Experimental Medicine
Torrey Pines Biolabs
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article
Right arrow Full Text
Right arrow Full Text (PDF, 146K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ravanel, K.
Right arrow Articles by Rabourdin-Combe, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ravanel, K.
Right arrow Articles by Rabourdin-Combe, C.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J. Exp. Med.
© The Rockefeller University Press
0022-1007/97/07/269/10 $2.00
Volume 186, Number 2, July 21, 1997 269-278

Measles Virus Nucleocapsid Protein Binds to Fcgamma RII and Inhibits Human B Cell Antibody Production

By Kissia Ravanel,* Claire Castelle,Dagger Thierry Defrance,§ T. Fabian Wild,§ Dominique Charron,Dagger Vincent Lotteau,par and Chantal Rabourdin-Combe*

From the * Immunobiologie Moléculaire, Unité Mixte de Recherche 49, Centre National de la Recherche Scientifique-Ecole Normale Supérieure Lyon, 69364 Lyon Cedex 07, France; Dagger  U396, Institut des Cordeliers, 75006 Paris, France; § U404, Institut Pasteur de Lyon, 69365 Lyon Cedex 07, France; and par  U391, 35043 Rennes Cedex, France

Despite the development of an efficient specific immune response during measles virus (MV) infection, an immunosuppression occurs contributing to secondary infections. To study the role of nucleocapsid protein (NP) in MV-induced immunosuppression, we produced recombinant MV NP. Purified recombinant NP exhibited biochemical, antigenic, and tridimensional structure similar to viral NP. By flow cytometry, we showed that viral or recombinant NP bound to human and murine B lymphocytes, but not to T lymphocytes. This binding was specific, independent of MHC class II expression, and dependent of the B lymphocyte activation state. The murine IIA1.6 B cell line, deficient in the Fc receptor for IgG (Fcgamma RII) expression, did not bind NP efficiently. Transfected IIA1.6 cells expressing either murine Fcgamma RIIb1 or b2, or human Fcgamma RIIa, b1*, or b2 isoforms efficiently bound NP. Furthermore, this binding was inhibited up to 90% by monoclonal antibodies 2.4G2 or KB61 specific for murine and human Fcgamma RII, respectively. Finally, the in vitro Ig synthesis of CD40- or Ig-activated human B lymphocytes in the presence of interleukin (IL)-2 and IL-10 was reduced by 50% in the presence of recombinant NP. These data demonstrate that MV NP binds to human and murine Fcgamma RII and inhibits in vitro antibody production, and therefore suggests a role for NP in MV-induced immunosuppression.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS